Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EpCAM-UPGs-MX
- Development stage
- Preclinical
- Lead developer
- Southeast University
- Modality
- Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**anti-EpCAM-UPGs-MX** is an experimental EpCAM-targeted theranostic nanomedicine developed for **hepatocellular carcinoma**. It consists of PEGylated upconversion nanoparticle-based micelles carrying the antineoplastic and photosensitizing agent **mitoxantrone**, with an anti-EpCAM antibody grafted to the micelle surface to promote delivery to EpCAM-positive hepatocellular carcinoma cells. Following intravenous administration in preclinical models, the formulation supported magnetic resonance and upconversion-luminescence imaging while producing combined mitoxantrone-mediated chemotherapy and photodynamic therapy after optical activation. The published work reported improved tumor-targeted imaging and antitumor activity relative to non-targeted comparator micelles.
- Other names
- anti-EpCAM-UPGs-MX
02
Targets
TOP2A (DNA topoisomerase II)EPCAM (Epithelial cell adhesion molecule)DNA
Beyond the preview
Go deeper on anti-EpCAM-UPGs-MX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EpCAM-UPGs-MX.